Uridine phosphorylase in breast cancer: A new prognostic factor?

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 2, 2006, Pages 2759-2766

  Yan, Ruilan ^a   Wan, Laxiang ^b   Pizzorno, Giuseppe ^b,c   Cao, Deliang ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

5 Fluorouracil; 5 Deoxy 5 fluorouridine; 5 DFUR; Breast Cancer; Capecitabine; Fluoropyrimidines; Gene Expression; Neoplasm; Prognostic Factor; Promoter; Pyrimidines; R bose 1 phosphate; Thymidine Phosphorylase; Uracil; Uridine; Uridine Phosphorylase

Indexed keywords

EID: 33744490347     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2005     Document Type: Review

References (76)

1. Cardini, C. E., A. C. Paladini, R. Caputto & L. F. Leloir: Liver uridine phosphorylase. Acta Physiol Lat Am 1, 57-63 (1950)
2. Cao, D., J. J. Leffert, J. McCabe, B. Kim & G. Pizzorno: Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 280, 21169-21175 (2005)
3. Newmark, P., J. D. Stephens & H. W. Barrett: Substrate specificity of the dihydro-uracil dhydrogenase and uridine phosphorylase of rat liver. Biochim Biophys Acta 62, 414-416 (1962)
4. Krenitsky, T. A., M. Barclay & J. A. Jacquez: Specificity Of Mouse Uridine Phosphorylase. Chromatography, Purification, And Properties. J Biol Chem 239, 805-812 (1964)
5. Bose, R. & E. W. Yamada: Uridine phosphorylase, molecular properties and mechanism of catalysis. Biochemistry 13, 2051-6205 (1974)
6. Cao, D. & G. Pizzorno: Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc) 40, 431-443 (2004)
7. Maring, J. G., H. J. Groen, F. M. Wachters, D. R. Uges & E. G. de Vries: Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5, 226-43 (2005)
8. Ardalan, B. & R. Glazer: An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev 8, 157-167 (1981)
9. Walton, L., C. A. Richards & L. P. Elwell: Nucleotide sequence of the Escherichia coli uridine phosphorylase (udp) gene. Nucleic Acids Res 17, 6741-6749 (1989)
10. Takehara, M., F. Ling, S. Izawa, Y. Inoue & A. Kimura: Molecular cloning and nucleotide sequence of purine nucleoside phosphorylase and uridine phosphorylase genes from Klebsiella sp. Biosci Biotechnol Biochem 59, 1987-1990 (1995)
11. Liu, M., D. Cao, R. Russell, R. E. Handschumacher & G. Pizzorno: Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 58, 5418-5424 (1998)
12. Watanabe, S., A. Hino, K. Wada, J. F. Eliason & T. Uchida: Purification, cloning, and expression of murine uridine phosphorylase. J Biol Chem 270, 12191-12196 (1995)
13. Cao, D., M. A. Nimmakayalu, F. Wang, D. Zhang, R. E. Handschumacher, P. Bray-Ward & G. Pizzorno: Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene. Cancer Res 59, 4997-5001 (1999)
14. Pizzorno, G., D. Cao, J. J. Leffert, R. L. Russell, D. Zhang & R. E. Handschumacher: Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 1587, 133-144 (2002)
15. Cao, D., R. L. Russell, D. Zhang, J. J. Leffert & G. Pizzorno: Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62, 2313-2317 (2002)
16. Wegelin, I., G. Pane & C. Clo: Studies of pyrimidine metabolism during chick development: two enzymes involved inUMP breakdown. Ital J Biochem 39, 361-367 (1990)
17. Frelin, C. & O. Bonnard: Uridine phosphorylase activity during postnatal development of the rat heart. Biol Neonate 37, 260-263 (1980)
18. Katsumata, K., H. Tomioka, T. Sumi, S. Yamashita, M. Takagi, F. Kato, R. Nakamura, Y. Koyanagi, T. Aoki & K. Kato: Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens. Cancer Chemother Pharmacol 51, 155-160 (2003)
19. Watanabe, S. & T. Uchida: Cloning and expression of human uridine phosphorylase. Biochem Biophys Res Commun 216, 265-272 (1995)
20. Schwartz, E. L., M. Hoffman, C. J. O'Connor & S. Wadler: Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 182, 1232-1239 (1992)
21. Eda, H., K. Fujimoto, S. Watanabe, T. Ishikawa, T. Ohiwa, K. Tatsuno, Y. Tanaka & H. Ishitsuka: Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5- fluorouridine. Jpn J Cancer Res 84, 341-347 (1993)
22. Wan, I., Cao, D., Zeng, j., Van, R., Pizzorno, G.: Modulation of uridine phosphorylase gene expression by tumor necrosis-alpha enhances the antiproliferative activity of capecitabine intermediate. Mol. Pharmacol (Jan 2006)
23. Geng, Y., E. Gheuens & E. A. de Bruijn: Activation and cytotoxicity of 5′-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells. Biochem Pharmacol 41, 301-303 (1991)
24. Zhang, D., D. Cao, R. Russell & G. Pizzomo: p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Res 61, 6899-6905 (2001)
25. Linke, S. P., K. C. Clarkin, A. Di Leonardo, A. Tsou & G. M. Wahl: A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10, 934-947 (1996)
26. Friedman, M. A. & W. Sadee: The fluoropyrimidines: biochemical mechanisms and design of clinical trials. Cancer Chemother Pharmacol 1, 77-82 (1978)
27. Grem, J. L.: 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18, 299-313 (2000)
28. Machover, D.: Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: pharmacologic and clinical aspects. J Surg Oncol Suppl 2, 42-50 (1991)
29. Peters, G. J., E. Laurensse, A. Leyva, J. Lankelma & H. M. Pinedo: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46, 20-28 (1986)
30. Peters, G. J., E. Laurensse, A. Leyva & H. M. Pinedo: The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites. Int J Biochem 17, 95-99 (1985)
31. Houghton, J. A. & P. J. Houghton: Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 19, 807-815 (1983)
32. Schwartz, P. M., R. D. Moir, C. M. Hyde, P. J. Turek & R. E. Handschumacher: Role of uridine phosphorylase in the anabolism of 5-fluorouracil. Biochem Pharmacol 34, 3585-3589 (1985)
33. Maehara, Y., S. Moriguchi, Y. Emi, A. Watanabe, S. Kohnoe, S. Tsujitani & K. Sugimachi: Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas. Cancer 66, 156-161 (1990)
34. Barankiewicz, J. & J. F. Henderson: Determination of ribose 1-phosphate in ascites tumor cells. Biochem Med 17, 45-53 (1977)
35. Laskin, J. D., R. M. Evans, H. K. Slocum, D. Burke & M. T. Hakala: Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res 39, 383-390 (1979)
36. Armstrong, R. D., K. M. Connolly, A. M. Kaplan & E. Cadman: Mechanism of cytotoxic activity of 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 11, 102-105 (1983)
37. Armstrong, R. D. & R. B. Diasio: Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res 40, 3333-3338 (1980)
38. Ishitsuka, H., M. Miwa, K. Takemoto, K. Fukuoka, A. Itoga & H. B. Maruyama: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71, 112-123 (1980)
39. Reyes, P. & T. C. Hall: Synthesis of 5-fluorouridine 5′-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumor-bearing mice. Biochem Pharmacol 18, 2587-2590 (1969)
40. Greenberg, N., D. E. Schumm & T. E. Webb: Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma. Biochem J 164, 379-387 (1977)
41. Inaba, M., J. Mitsuhashi, H. Sawada, N. Miike, Y. Naoe, A. Daimon, K. Koizumi, H. Tsujimoto & M. Fukushima: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 87, 212-220 (1996)
42. Chung, Y. M., S. Park, J. K. Park, Y. Kim, Y. Kang & Y. D. Yoo: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159, 95-101 (2000)
43. Ikenaka, K., T. Shirasaka, S. Kitano & S. Fujii: Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 70, 353-359 (1979)
44. Kessel, D. & T. C. Hall: Influence of ribose donors on the action of 5-fluorouracil. Cancer Res 29, 1749-1754 (1969)
45. Gotto, A. M., M. L. Belkhode & O. Touster: Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14-C, 5-fluorouracil-2-14-C, and 5-bromouracil-2-14-C into nucleic acids by Ehrlich ascites tumor cells in vitro. Cancer Res 29, 807-811 (1969)
46. Au, J. L., Y. M. Rustum, J. Minowada & B. I. Srivastava: Differential selectivity of 5-fluorouracil and 5′-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia. Biochem Pharmacol 32, 541-546 (1983)
47. Malet-Martino, M., P. Jolimaitre & R. Martino: The prodrugs of 5-fluorouracil. Curr Med Chem Anti-Canc Agents 2, 267-310 (2002)
48. Malet-Martino, M. & R. Martino: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7, 288-323 (2002)
49. de Bruijn, E. A., A. T. van Oosterom, U. R. Tjaden, H. J. Reeuwijk & H. M. Pinedo: Pharmacology of 5′-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res 45, 5931-5935 (1985)
50. Sommadossi, J. P., C. Aubert, J. P. Cano, J. Gouveia, P. Ribaud & G. Mathe: Kinetics and metabolism of a new fluoropyrimidine, 5′-deoxy-5- fluorouridine, in humans. Cancer Res 43, 930-933 (1983)
51. Cory, J. G. & G. L. Carter: Evidence that 5′-deoxy-5- fluorouridine may not be activated by the same mechanism as 5-fluorouracil. Biochem Pharmacol 31, 2841-2844 (1982)
52. Wagstaff, A. J., T. Ibbotson & K. L. Goa: Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 63, 217-236 (2003)
53. Venturini, M.: Rational development of capecitabine. Eur J Cancer 38, 3-9 (2002)
54. Reigner, B., K. Blesch & E. Weidekamm: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40, 85-104 (2001)
55. Ishikawa, T., M. Utoh, N. Sawada, M. Nishida, Y. Fukase, F. Sekiguchi & H. Ishitsuka: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55, 1091-1097 (1998)
56. Schuller, J., J. Cassidy, E. Dumont, B. Roos, S. Durston, L. Banken, M. Utoh, K. Mori, E. Weidekamm & B. Reigner: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45, 291-297 (2000)
57. Mader, R. M., C. Schrolnberger, B. Rizovski, M. Brunner, C. Wenzel, G. Locker, H. G. Eichler, M. Mueller & G. G. Steger: Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer 88, 782-787 (2003)
58. Endo, M., N. Shinbori, Y. Fukase, N. Sawada, T. Ishikawa, H. Ishitsuka & Y. Tanaka: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83, 127-134 (1999)
59. Monta, T., A. Matsuzaki & A. Tokue: Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 92, 451-456 (2001)
60. Sivridis, E.: Thymidine phosphorylase activity in normal, hyperplastic and neoplastic endometrium-correlation with intratumoral angiogenesis. Adv Exp Med Biol 476, 297-303 (2000)
61. Griffiths, L. & I. J. Stratford: Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 76, 689-693 (1997)
62. Ishikawa, F., K. Miyazono, U. Hellman, H. Drexler, C. Wernstedt, K. Hagiwara, K. Usuki, F. Takaku, W. Risau & C. H. Heldin: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338, 557-562 (1989)
63. Kanzaki, A., Y. Takebayashi, H. Bando, J. F. Eliason, S. Watanabe Si, H. Miyashita, M. Fukumoto, M. Toi & T. Uchida: Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. Int J Cancer 97, 631-635 (2002)
64. el Kouni, M. H., M. M. el Kouni & F. N. Naguib: Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res 53, 3687-3693 (1993)
65. Brown, N. S. & R. Bicknell: Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 334, 1-8 (1998)
66. Focher, F. & S. Spadari: Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy. Curr Cancer Drug Targets 1, 141-153 (2001)
67. Link, K. H., M. Kornmann, L. Staib, M. Redenbacher, M. Kron & H. G. Beger: Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg 242, 178-187 (2005)
68. Finan, P. J., P. A. Koklitis, E. M. Chisholm & G. R. Giles: Comparative levels of tissue enzymes concerned in the early metabolism of 5-fluorouracil in normal and malignant human colorectal tissue. Br J Cancer 50, 711-715 (1984)
69. Luccioni, C., J. Beaumatin, V. Bardot & D. Lefrancois: Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int J Cancer 58, 517-522 (1994)
70. Leyva, A., I. Kraal, J. Lankelma, J. F. Delemarre & H. M. Pinedo: High uridine phosphorylase activity in human melanoma tumor. Anticancer Res 3, 227-231 (1983)
71. Leyva, A., I. Kraal, J. Lankelma & H. M. Pinedo: High uridine catabolic activity in cultured human melanoma cells. Adv Exp Med Biol 165 Pt B, 395-399 (1984)
72. Miyashita, H., Y. Takebayashi, J. F. Eliason, F. Fujimori, Y. Nitta, A. Sato, H. Morikawa, A. Ohashi, K. Motegi, M. Fukumoto, S. Mori & T. Uchida: Uridine phosphorylase is a potential prognostic factor in patients with oral squamous cell carcinoma. Cancer 94, 2959-2966 (2002)
73. Denton, J. E., M. S. Lui, T. Aoki, J. Sebolt, E. Takeda, J. N. Eble, J. L. Glover & G. Weber: Enzymology of pyrimidine and carbohydrate metabolism in human colon carcinomas. Cancer Res 42, 1176-1183 (1982)
74. Takebayashi, Y., S. Akiyama, S. Akiba, K. Yamada, K. Miyadera, T. Sumizawa, Y. Yamada, F. Murata & T. Aikou: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88, 1110-1117 (1996)
75. Hiraga, T., K. Hata, F. Ikeda, J. Kitagaki, K. Fujimoto-Ouchi, Y. Tanaka & T. Yoneda: Preferential inhibition of bone metastases by 5′-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model. Oncol Rep 14, 695-699 (2005)
76. Cuq, P., C. Rouquet, A. Evrard, J. Ciccolini, L. Vian & J. P. Cano: Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase. Br J Cancer 84, 1677-1680 (2001)